Intellia Therapeutics Shares Outstanding 2015-2021 | NTLA

Intellia Therapeutics shares outstanding history from 2015 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Intellia Therapeutics shares outstanding for the quarter ending June 30, 2021 were 0.068B, a 27.72% increase year-over-year.
  • Intellia Therapeutics 2020 shares outstanding were 0.056B, a 18.5% increase from 2019.
  • Intellia Therapeutics 2019 shares outstanding were 0.047B, a 9.7% increase from 2018.
  • Intellia Therapeutics 2018 shares outstanding were 0.043B, a 19.62% increase from 2017.
Intellia Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 56
2019 47
2018 43
2017 36
2016 22
2015 0
2014
Intellia Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 68
2021-03-31 67
2020-12-31 56
2020-09-30 59
2020-06-30 53
2020-03-31 50
2019-12-31 47
2019-09-30 49
2019-06-30 46
2019-03-31 45
2018-12-31 43
2018-09-30 43
2018-06-30 43
2018-03-31 42
2017-12-31 36
2017-09-30 35
2017-06-30 35
2017-03-31 35
2016-12-31 22
2016-09-30 34
2016-06-30 19
2016-03-31 1
2015-12-31 0
2015-09-30 0
2015-06-30 1
2015-03-31 1
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.863B $0.058B
Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57